WNK2 and cancer: BRAF mutations are well known as oncogenic drivers in several cancers and are found in approximately 6% of all cases of metastatic cancer.1 Activating BRAF mutations lead to constitutive activation of the mitogen-activated protein kinase (MAPK) pathway resulting in uncontrolled cell proliferation, dedifferentiation, and cell survival.2 The most common BRAF mutation in human cancer is the BRAF V600E mutation.3,4